Facts
- Congress amended the Federal Food, Drug, and Cosmetic Act (FFDCA) in 1962 to require prescription drug labeling to display the drug’s established (generic) name prominently and in type at least half as large as any proprietary (brand) name.
- The FDA Commissioner issued regulations requiring the established name to accompany each appearance of a proprietary name on labels and advertisements (the “every time” rule).
- Abbott Laboratories and other prescription drug manufacturers challenged the regulations as exceeding the Commissioner’s statutory authority.
- The district court granted declaratory and injunctive relief, concluding the regulations were broader than the statute authorized.
- The court of appeals reversed without reaching the merits, holding pre-enforcement review was unavailable and that there was no justiciable controversy under the Administrative Procedure Act (APA) or Declaratory Judgment Act (DJA).
- The Supreme Court granted review to decide whether the challenge could be heard before enforcement and whether the dispute was ripe.
Issues
- Whether the FFDCA precludes pre-enforcement judicial review of the FDA’s labeling regulations.
- Whether the manufacturers’ challenge was ripe for judicial review under Article III and the APA/DJA, given the absence of an enforcement action.
Decision
- The Supreme Court reversed the court of appeals and remanded for consideration of the regulations’ substantive validity.
- The Court held the FFDCA did not bar pre-enforcement review of the “every time” rule.
- The Court held the controversy was ripe because the issues were fit for judicial decision and withholding review would cause substantial hardship to the manufacturers.
Legal Principles
- Judicial review of administrative action is presumed available; review is restricted only upon “clear and convincing” evidence of congressional intent to preclude it.
- A specialized statutory review provision does not, by itself, exclude other avenues of review, particularly where the statute contains a saving clause preserving other legal remedies.
- Ripeness for pre-enforcement review turns on (1) the fitness of the issues for judicial decision and (2) the hardship to the parties of withholding court consideration.
- Fitness is satisfied where the challenge presents a primarily legal question and the agency action is final (including regulations formally promulgated through notice-and-comment).
- Hardship is satisfied where a regulation requires immediate and significant changes in regulated conduct, imposes substantial compliance costs, or forces regulated parties to risk serious civil or criminal penalties to obtain review.
Conclusion
The Court permitted a pre-enforcement challenge to the FDA’s labeling regulation, holding the FFDCA did not foreclose judicial review and that the dispute was ripe under a two-part test focusing on the legal fitness of the issues and the practical hardship of withholding review.